Sign in
Taking people in United StatesPhase 2

A Study to Learn About mRNA Vaccines Against Influenza in Adults

Key facts

Who runs it
Pfizer
Where
Charlottesville, Hialeah, Honolulu, Kansas City, Mesquite, Miami Lakes, Milford, Mobile, Philadelphia, Rochester, Salt Lake City, Stockbridge, Tomball, Walnut Creek, and Washington D.C., United StatesSee the 15 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
770 people, planned
Started
23 Feb 2026
Expected to end
22 Jun 2027
Type of study
Interventional, 7 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vaccine Candidate #1
  • Vaccine Candidate #2
  • Vaccine Candidate #3
  • Vaccine Candidate #4
  • Vaccine Candidate #5
  • Vaccine Candidate #6
  • TIV1 or TIV2
Record updated
6 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Healthy and medically stable participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study

Who cannot take part

  • Tested positive for influenza ≤5 months (150 days) prior to Visit 1 (Day 1)
  • Vaccination with any investigational or licensed influenza vaccine ≤5 months (150 days) before Visit 1 (Day 1)
  • Receipt of antiviral therapies for influenza (eg, Tamiflu) ≤5 months (150 days) prior to Visit 1 (Day 1)

Where in United States

  • Charlottesville Medical Research Center, LLCCharlottesville, United StatesTaking people
  • Indago Research & Health Center, IncHialeah, United StatesTaking people
  • East-West Medical Research InstituteHonolulu, United StatesTaking people
  • AMR ClinicalKansas City, United StatesTaking people
  • SMS Clinical Research, LLCMesquite, United StatesTaking people
  • Palm Springs Community Health CenterMiami Lakes, United StatesTaking people
  • Clinical Research Consulting, LLCMilford, United StatesTaking people
  • AMR ClinicalMobile, United StatesTaking people
  • DM Clinical Research - PhiladelphiaPhiladelphia, United StatesTaking people
  • Rochester Clinical Research, LLCRochester, United StatesTaking people
  • J. Lewis Research, Inc. / Foothill Family ClinicSalt Lake City, United StatesTaking people
  • Clinical Research AtlantaStockbridge, United StatesTaking people
  • DM Clinical ResearchTomball, United StatesTaking people
  • Diablo Clinical Research, LLC d/b/a Flourish ResearchWalnut Creek, United StatesTaking people
  • George Washington Medical Faculty AssociatesWashington D.C., United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus).

Read full original descriptionShow less

This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison.

Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.

The 7 groups in the trial

  • ATreatment being tested

    mRNA influenza vaccine candidate #1 as a single intramuscular (IM) injection on Day 1.

    Treatment: Vaccine Candidate #1

  • BTreatment being tested

    mRNA influenza vaccine candidate #2 as a single IM injection on Day 1.

    Treatment: Vaccine Candidate #2

  • CTreatment being tested

    mRNA influenza vaccine candidate #3 as a single IM injection on Day 1.

    Treatment: Vaccine Candidate #3

  • DTreatment being tested

    mRNA influenza vaccine candidate #4 as a single IM injection on Day 1.

    Treatment: Vaccine Candidate #4

  • ETreatment being tested

    mRNA influenza vaccine candidate #5 as a single IM injection on Day 1.

    Treatment: Vaccine Candidate #5

  • FTreatment being tested

    mRNA influenza vaccine candidate #6 as a single IM injection on Day 1.

    Treatment: Vaccine Candidate #6

  • GExisting treatment, for comparison

    Licensed influenza vaccine (TIV1 or TIV2) as a single IM injection.

    Treatment: TIV1 or TIV2

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA VACCINES AGAINST INFLUENZA IN ADULTS 18 YEARS OF AGE AND OLDER
Record updated
6 May 2026